Tenon Medical Files S-1/A Amendment
Ticker: TNONW · Form: S-1/A · Filed: Jun 21, 2024 · CIK: 1560293
| Field | Detail |
|---|---|
| Company | Tenon Medical, Inc. (TNONW) |
| Form Type | S-1/A |
| Filed Date | Jun 21, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.001, $100,000, $9.9 million, $0.5907, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, s-1/a, securities-offering
TL;DR
Tenon Medical filed an S-1/A amendment, likely for a stock offering. Watch for updates.
AI Summary
Tenon Medical, Inc. filed an S-1/A amendment on June 20, 2024, for its registration statement (No. 333-279336). The filing details the company's business, including its principal executive offices located at 104 Cooper Court, Los Gatos, CA 95032, and its CEO, Steven M. Foster. This amendment likely provides updated information or corrections to its initial S-1 filing regarding its securities offering.
Why It Matters
This S-1/A filing indicates Tenon Medical is moving forward with a securities offering, which could impact its capital structure and future operations.
Risk Assessment
Risk Level: medium — S-1/A filings are related to securities offerings, which inherently carry risks for investors and the company.
Key Numbers
- 333-279336 — SEC Registration Number (Identifies the specific securities offering registration.)
- 241058268 — Film Number (Internal SEC processing number for the filing.)
Key Players & Entities
- Tenon Medical, Inc. (company) — Registrant
- June 20, 2024 (date) — Filing Date
- 333-279336 (registration_number) — SEC Registration Number
- 104 Cooper Court, Los Gatos, CA 95032 (address) — Principal Executive Offices
- Steven M. Foster (person) — Chief Executive Officer and President
- Sichenzia Ross (company) — Legal Counsel
FAQ
What specific changes or updates does this S-1/A amendment introduce compared to the original S-1 filing?
The provided text does not detail the specific changes made in this Amendment No. 1 to Form S-1. It only states that it is an amendment to the registration statement.
What is the primary purpose of Tenon Medical, Inc.'s S-1/A filing?
The S-1/A filing is an amendment to a registration statement under the Securities Act of 1933, indicating the company is preparing to offer securities to the public.
Who is the Chief Executive Officer and President of Tenon Medical, Inc.?
Steven M. Foster is the Chief Executive Officer and President of Tenon Medical, Inc.
Where are Tenon Medical, Inc.'s principal executive offices located?
Tenon Medical, Inc.'s principal executive offices are located at 104 Cooper Court, Los Gatos, CA 95032.
What is the Standard Industrial Classification (SIC) code for Tenon Medical, Inc.?
The Standard Industrial Classification (SIC) code for Tenon Medical, Inc. is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
Filing Stats: 4,594 words · 18 min read · ~15 pages · Grade level 14.4 · Accepted 2024-06-20 22:01:04
Key Financial Figures
- $0.001 — 0 shares of our common stock, par value $0.001 per share, by the selling stockholder,
- $100,000 — r total gross proceeds of approximately $100,000 pursuant to the Original Registration S
- $9.9 million — e gross proceeds of up to approximately $9.9 million from any sale of our common stock to Li
- $0.5907 — ported on The Nasdaq Capital Market was $0.5907. You are urged to obtain current market
- $1.00 — intained a minimum closing bid price of $1.00 per share required for continued listin
- $1.2705 — n Stock") at an exercise price equal to $1.2705 per share for an aggregate offering pri
- $2,605,000 — hare for an aggregate offering price of $2,605,000. Under the Series A Purchase Agreement,
- $15.125 — Agreement, each Series A Investor paid $15.125 for each share of Series A Preferred St
- $1,250,000 — ering (the "Note Offering"), a total of $1,250,000 in secured notes (the "Notes") and warr
- $1.94 — mon stock at an exercise price equal to $1.94 per share. The Company received $1,125,
- $1,125,000 — o $1.94 per share. The Company received $1,125,000 from the Note Offering after payment of
Filing Documents
- ea0208117-s1a1_tenonmed.htm (S-1/A) — 2188KB
- ea020811701ex23-1_tenonmedi.htm (EX-23.1) — 3KB
- ea020811701ex23-2_tenonmedi.htm (EX-23.2) — 3KB
- image_001.jpg (GRAPHIC) — 7KB
- image_002.jpg (GRAPHIC) — 14KB
- image_003.jpg (GRAPHIC) — 5KB
- image_004.jpg (GRAPHIC) — 14KB
- image_005.jpg (GRAPHIC) — 10KB
- image_006.jpg (GRAPHIC) — 28KB
- image_007.jpg (GRAPHIC) — 5KB
- image_008.jpg (GRAPHIC) — 28KB
- image_009.jpg (GRAPHIC) — 9KB
- image_010.jpg (GRAPHIC) — 6KB
- image_011.jpg (GRAPHIC) — 5KB
- image_012.jpg (GRAPHIC) — 11KB
- image_013.jpg (GRAPHIC) — 4KB
- image_014.jpg (GRAPHIC) — 7KB
- ex23-2_001.jpg (GRAPHIC) — 2KB
- ex23-2_002.jpg (GRAPHIC) — 2KB
- 0001213900-24-054447.txt ( ) — 8990KB
- tnon-20240331.xsd (EX-101.SCH) — 71KB
- tnon-20240331_cal.xml (EX-101.CAL) — 54KB
- tnon-20240331_def.xml (EX-101.DEF) — 405KB
- tnon-20240331_lab.xml (EX-101.LAB) — 646KB
- tnon-20240331_pre.xml (EX-101.PRE) — 417KB
- ea0208117-s1a1_tenonmed_htm.xml (XML) — 843KB
RISK FACTORS
RISK FACTORS 10 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 45
USE OF PROCEEDS
USE OF PROCEEDS 46 DIVIDEND POLICY 46 MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS 46 LINCOLN PARK TRANSACTION 48 SELLING STOCKHOLDER 54
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 55
BUSINESS
BUSINESS 66 MANAGEMENT 84
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 90 PRINCIPAL STOCKHOLDERS 99 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 101
DESCRIPTION OF SECURITIES
DESCRIPTION OF SECURITIES 101 PLAN OF DISTRIBUTION 108 EXPERTS 109 CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT 109 LEGAL MATTERS 110 WHERE YOU CAN FIND MORE INFORMATION 110 INDEX TO FINANCIAL STATEMENTS F-1 We have not, and the Selling Stockholder has not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give to you. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of our common stock. You should rely only on the information contained in this prospectus. No dealer, salesperson or other person is authorized to give information that is not contained in this prospectus. This prospectus is not an offer to sell nor is it seeking an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of these securities. i ABOUT THIS PROSPECTUS Throughout this prospectus, unless otherwise designated or the context suggests otherwise, all references to the "Tenon," the "Company," the "registrant," "we," "our," or "us" in this prospectus mean Tenon Medical, Inc.; "year" or "fiscal year" means the year ending December 31 st ; and all dollar or $ references, when used in this prospectus, refer to United States dollars. assumes all 410,153 Original Purchase Shares covered by the Original Registration Statement have been purchased by Lincoln Park. Market Data Market data and certain industry data and forecasts used throughout this prospectus were obtained from in